COVID-19 Immunity Testing: A Passport to Inequity
By Françoise Baylis and Natalie Kofler,
Issues in Science and Technology
| 04. 29. 2020
In an already heavily stratified society, the introduction of immunity passports is ethically problematic. They would not only exacerbate current inequities but also create a novel layer of biological inequity.
As COVID-19 case numbers start to plateau in various places, some governments are now focusing on how best to ease restrictions and reopen the economy. In the absence of herd immunity for the population—for which the threshold may be as high as 82%—next steps are not obvious.
Recently, some have touted “immunity passports” for people who have survived infection with SARS-CoV-2 (the novel coronavirus that causes COVID-19) and tested positive for SARS-CoV-2 antibodies. Under this proposal, citizens deemed immune to the virus through serological testing (a type of blood test) could be freed from current restrictions and allowed to return to work. According to media reports, Chile is poised to become the first country to issue some kind of immunity cards. Others considering this option include Australia, Germany, Italy, the United Kingdom, and the United States.
In an already heavily stratified society, the introduction of immunity passports is ethically problematic. They would not only exacerbate current inequities but also create a novel layer of biological inequity—one based on a potentially ineffective measure of immunity.
Infection with...
Related Articles
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Alfonso Martinez Arias, Nicolas Rivron, and Naomi Moris, BioNews | 04.20.2026
By George Janes, BioNews | 04.20.2026
New regulations in sperm donation are being implemented by Belgium's Federal Agency for Medicines and Health Products (FAMHP), following revelations regarding the use of sperm carrying a cancer-causing mutation, and widespread breaches of donor limits.
In 2025, it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...